Health & Wellness Blog - Page 42

Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect

Eli Lilly has launched Foundayo, its innovative oral GLP-1 drug, directly to U.S. consumers via LillyDirect and major telehealth providers. This once-daily pill offers convenient obesity treatment alongside diet and exercise, with average weight loss of 27 pounds at the highest dose. Now available through Amazon Pharmacy's same-day delivery and more, it's set to challenge Novo's Wegovy dominance.

Shotlee·Apr 9, 2026·5 min read

GLP-1 Medications

Cheaper Generic Semaglutide in India: Experts Warn Against Quick-Fix Use

Cheaper generic semaglutide is transforming access to weight loss and diabetes treatment in India, priced at just Rs750 per weekly injection. However, experts caution against 'quick-fix' use without medical oversight, highlighting risks like 40% muscle loss from lean mass. Discover clinical evidence from STEP-1 and SELECT trials and why structured care is essential.

Shotlee·Apr 9, 2026·5 min read

GLP-1 Medications

Untold Dangers of GLP-1s: Ozempic, Wegovy & Mounjaro Risks

Wegovy, Ozempic, and Mounjaro promise effortless weight loss with minimal risk, but new research uncovers deeper dangers like altered brain chemistry and loss of desire. On The Spectacle Podcast, Scott McKay and Melissa Mackenzie dive into the science, Melissa's personal story, and why lifestyle changes offer a safer path.

Shotlee·Apr 9, 2026·5 min read

GLP-1 Medications

EU Approves Easier Wegovy Delivery, Easing Cold Chain Rules

Novo Nordisk has won EU regulatory approval to ease cold chain requirements for Wegovy injections, marking the first GLP-1 therapy in Europe with such delivery flexibility. The change allows a 48-hour window without refrigeration from pharmacies to patients, streamlining distribution and enhancing access. This aligns with trends in direct-to-patient models and complements recent subscription programs for better affordability.

Shotlee·Apr 9, 2026·5 min read

Regulatory Affairs

Time for Guardrails on GLP-1 Compounding: Safety Risks Exposed

America faces a crisis in unregulated compounded GLP-1 drugs, with FDA reporting 1,150 adverse events including hospitalizations and deaths. Exploiting shortages of semaglutide and tirzepatide, compounders flood the market with untested products, misleading consumers. Now, with the SAFE Drugs Act and FDA crackdowns, it's time to restore safety standards.

Shotlee·Apr 8, 2026·4 min read

Peptide Therapy

Can Biopeptides Reclaim Weight Loss from GLP-1 Drugs?

As GLP-1 drugs like Ozempic transform weight loss, biotech startup Lembas argues biopeptides can reclaim a role through food-based satiety support. CEO Shay Hillel, speaking at Future Food-Tech San Francisco, positions these short proteins as complements—not replacements—for better metabolic health. With clinical trials underway, functional foods may soon enhance GLP-1 therapy.

Shotlee·Apr 8, 2026·5 min read

Metabolic Health

ROOT Brands® Fills GLP-1 Gap with CRUSH™ & SCULPT™ After Ozempic® & Wegovy®

As millions using GLP-1 medications like Ozempic® and Wegovy® face post-treatment challenges such as muscle loss and weight regain, ROOT Brands® introduces CRUSH™ and SCULPT™. This cellular-first protocol supports metabolic function and lean muscle preservation without pharmaceuticals. Backed by science, it targets the 'GLP-1 gap' for long-term body composition success.

Shotlee·Apr 8, 2026·5 min read

GLP-1 Medications

What to Know If Taking Weight Loss Drugs Like Ozempic

Roughly half a million Australians are using GLP-1 weight loss drugs like Ozempic and Mounjaro, with some reporting life-changing results while others face side effects. Professor Kelly Lambert from the University of Wollongong shares key insights on what you need to know. This guide covers mechanisms, safety, and practical tips for users.

Shotlee·Apr 8, 2026·5 min read

GLP-1 Medications

23andMe Study: Genetic Changes Predict GLP-1 Response for Weight Loss

A groundbreaking 23andMe study published in Nature identifies specific genetic changes in two genes that predict how well patients respond to GLP-1 drugs for weight loss—and whether they'll experience common side effects like nausea or vomiting. Led by Adam Auton, the research offers proof of concept for genetics in GLP-1 therapy. While experts are intrigued, questions remain on clinical impact.

Shotlee·Apr 8, 2026·4 min read

Latest Articles

Latest Articles

Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect

Cheaper Generic Semaglutide in India: Experts Warn Against Quick-Fix Use

Untold Dangers of GLP-1s: Ozempic, Wegovy & Mounjaro Risks

EU Approves Easier Wegovy Delivery, Easing Cold Chain Rules

Time for Guardrails on GLP-1 Compounding: Safety Risks Exposed

Can Biopeptides Reclaim Weight Loss from GLP-1 Drugs?

ROOT Brands® Fills GLP-1 Gap with CRUSH™ & SCULPT™ After Ozempic® & Wegovy®

What to Know If Taking Weight Loss Drugs Like Ozempic

23andMe Study: Genetic Changes Predict GLP-1 Response for Weight Loss

Latest Articles

Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect

Cheaper Generic Semaglutide in India: Experts Warn Against Quick-Fix Use

Untold Dangers of GLP-1s: Ozempic, Wegovy & Mounjaro Risks

EU Approves Easier Wegovy Delivery, Easing Cold Chain Rules

Time for Guardrails on GLP-1 Compounding: Safety Risks Exposed

Can Biopeptides Reclaim Weight Loss from GLP-1 Drugs?

ROOT Brands® Fills GLP-1 Gap with CRUSH™ & SCULPT™ After Ozempic® & Wegovy®

What to Know If Taking Weight Loss Drugs Like Ozempic

23andMe Study: Genetic Changes Predict GLP-1 Response for Weight Loss